JenaValve Technology, Inc.
Company Details
Status: Private
Employees: 101-250
Location:
4 Cromwell, Suite 100, Irvine, CA 92618, US
Type:
sample
sample
Technology:
sample
sample
About: JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR).
The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis.
In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR.
JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
JenaValve Technology, Inc. | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.